Your email has been successfully added to our mailing list.

×
-0.0280985116465328 -0.0280985116465328 -0.0280985116465328 -0.0280985116465328 -0.0280985116465328 -0.0211573116198359 -0.0211573116198359 -0.00807581926183013
Stock impact report

FDA Approves New Sleep Drug With Claims Of Less Risk Of Unpleasant Side Effects [Forbes]

EISAI CO S/ADR (ESALY) 
NASDAQ:AMEX Investor Relations: eisai.com/ir/index.html
Company Research Source: Forbes
For those who suffer from insomnia, the answer is not simple. Of the few medications on the market, many cause a slew of unpleasant and sometimes dangerous side effects. However, recently the FDA approved a new insomnia medication that may serve as an alternative. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep. Dayvigo was approved for the treatment of insomnia in adults who demonstrated difficulty falling asleep and staying asleep. Drug makers believe the drug may be particularly beneficial to seniors suffering from sleep problems related to mild to moderate Alzheimer’s disease In studies, the Dayvigo was found to statistically improve sleep onset and keep patients asleep,when compared to the placebo. Dayvigo was also not found to cause rebound insomnia, a common problem with some sleep medications. This describes worsened sleep compared to the baseline after drug discontinuation. There was also no evidence of withdrawal effects. The most c Show less Read more
Impact Snapshot
Event Time:
ESALY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ESALY alerts
Opt-in for
ESALY alerts

from News Quantified
Opt-in for
ESALY alerts

from News Quantified